Dedicated bifurcation stents or regular drug eluting stents in distal left main stenosis: A retrospective study

Abstract

Background: In the distal left main (LM) atherosclerosis mainly develops within bifurcation or trifurcation. The aim of this study was to analyze the strategy of distal LM stenosis treatment and associated clinical outcomes in a large (BiOSS 12.5% vs. rDES 9.6%). In logistic regression for 36-month TLR rate proximal optimization technique (OR 0.311,) was a prognostic factor of better clinical outcome, whereas non-ST-elevation ACS (OR 2.211,, MACE and TLR rates. (Cardiol J 2018; 25, 2: 188-195)

Safety and efficacy of self‐apposing Stentys drug‐eluting stent in left main coronary artery PCI: Multicentre LM‐STENTYS registry

“…Covering the SB ostium, which is facilitated by Stentys DES architecture, could decrease the need for second stent implantation. Indeed, the rate of SB stenting in the current study was low and comparable to other dedicated bifurcation DES such as Bioss LIM (Balton, Warsaw, Poland) . notwithstanding, it was lower than in other previously tested stents .…”

First-in-man study of dedicated bifurcation cobalt-chromium sirolimus-eluting stent BiOSS LIM C® — three-month results

“…The first BiOSS ® stent was a bare metal one (stainless steel), but shortly after, a paclitaxel-eluting version was introduced into the market -the BiOSS Expert ® stent (CE Mark 2010), and in 2012 the sirolimus-eluting BiOSS LIM ® stent was developed. The obtained results in registries and clinical trials [8][9][10][11][12][13] as well as in everyday practice were satisfactory [14][15][16], but still a means of improvement has been sought. Therefore, a cobalt-chromium sirolimus-eluting version has been developed, i.e.…”